Drug intelligence / Profile preview

AM1944

Development stage: Preclinical
Lead developer: Moderna
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics, Gene Silencing → Gene Therapies, Gene Editing → Gene Therapies
Administration: Implant

Overview

AM1944 is a preclinical-stage mRNA-eluting biodegradable implant being developed by AMW GmbH as a next-generation gene therapy and vaccine technology platform. Utilizing AMW's proprietary controlled-release formulation technology, the implant is designed to provide sustained delivery of mRNA directly to target tissues, minimizing systemic exposure and reducing dosing frequency. Prototyping and plausibility studies have been concluded, with initial development focusing on applications in prostate cancer and breast cancer.

Other names: AM-1944AM1944AM 1944

Beyond the preview

Go deeper on AM1944.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AM1944.

Explore the full profile